Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04776330 | a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease | PHASE1 | RECRUITING | 80 | — | — | Mar 7, 2021 | Jul 1, 2027 | Feb 25, 2025 | 1 | China |
Therapy-related adverse events will be recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0)
The response rate of BCMA targeted prime CAR-T treatment will be recorded and assessed according to the IMWG
| Arm | Type | Description |
|---|---|---|
| BCMA targeted prime CAR-T cells treat | EXPERIMENTAL | Patients will be be treated with BCMA targeted prime CAR-T cells |
| Name | Type | Description |
|---|---|---|
| BCMA targeted prime CAR-T cells | BIOLOGICAL | BCMA targeted prime CAR-T cell therapy |
Inclusion Criteria: 1. Signed written informed consent; 2. Diagnose as relapsed /refractory multiple myeloma or other plasma cell disease, and meet one of the following conditions: 1. Failed to standard chemotherapy regimens; 2. Relapse after complete remission, high-risk and / or refractory...